Search

Your search keyword '"Nina Raulf"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Nina Raulf" Remove constraint Author: "Nina Raulf"
22 results on '"Nina Raulf"'

Search Results

1. 515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours

2. MicroRNA‐9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4

3. 850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies

4. Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade

5. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

6. 515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours

7. Developing small activating RNA as a therapeutic: current challenges and promises

8. MicroRNA‐9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4

9. Abstract 1730: Up-regulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients

10. Clinical update on head and neck cancer: molecular biology and ongoing challenges

11. Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

12. First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)

13. Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers

14. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance

15. Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10

16. Cytosolic Bax

17. PO-199 Lysyl oxidase in head and neck cancer: metastasis and therapy response

18. PO-164 Modulation of EGFR to overcome tumour resistance and improve radiotherapy response in HPV positive and negative head and neck cancer cells

19. NIR an inhibitor of histone acetyltransferases regulates transcription factor TAp63 and is controlled by the cell cycle

20. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism

21. MicroRNA-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance

22. Cytosolic Bax: does it require binding proteins to keep its pro-apoptotic activity in check?

Catalog

Books, media, physical & digital resources